Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

(2011) Tamara Castillo-Trivino et al.   PLoS One

A method for evaluating treatment switching criteria in multiple sclerosis

(2010) Brian C Healy et al.   Multiple Sclerosis Journal

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

(2009) A. B. Oturai et al.   EUROPEAN JOURNAL OF NEUROLOGY

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Predicting responders to therapies for multiple sclerosis

(2009) Jordi Río et al.   Nature Reviews Neurology

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina

(2008) A. Carrá et al.   EUROPEAN JOURNAL OF NEUROLOGY

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders

(2008) L. Durelli et al.   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis

(2008) A Gajofatto et al.   Multiple Sclerosis Journal